Bridge Pharma (United States)

Recent papers from Bridge Pharma (United States)

1. Nationwide US federated deployment of artificial intelligence for multimodal screening of ATTR cardiomyopathy: first multicenter analysis from the TRACE networkEuropean Heart Journal · 2026
2. Adherence and legacy effects of high dose eicosapentaenoic acid in hypertriglyceridemia and high CV risk – REDUCE-IT LegacyEuropean Heart Journal · 2026
3. Patient-Reported Benefits of Acoramidis Across Genotypes in Transthyretin Amyloid Cardiomyopathy: KCCQ and EQ-5D-5L Outcomes From ATTRibute-CMJournal of Cardiac Failure · 2026
4. Comparative efficacy and safety of acoramidis versus tafamidis in patients with transthyretin amyloid cardiomyopathy: an anchored matching-adjusted indirect comparisonEuropean Heart Journal Open · 2026
5. Comparative Effectiveness of TTR Stabilizers for the Treatment of ATTR-CM Using Real-World EvidenceCardiology and Therapy · 2026
6. Barrier identification and strategic design for hypertriglyceridemia management in the post-acute coronary syndrome patient population at a large integrated health systemAmerican Heart Journal Plus Cardiology Research and Practice · 2026
7. In Participants Treated With Acoramidis, Addition of Concomitant Tafamidis Did Not Further Increase Serum TTR LevelsJournal of the American College of Cardiology · 2025
8. Artificial Intelligence, Firm Productivity, and Macroeconomic Performance: A Systematic Evidence Synthesis and the AI Productivity Contingency Framework (AIPCF)2026
9. Natriuretic Peptide and Transthyretin and Their Relationship With Clinical Outcomes: Results From ATTRIBUTE‐CM, a Randomized Controlled TrialJournal of the American Heart Association · 2026
10. Asymptomatic Carrier Neurologic Assessment: A Tool for Early Detection of Symptomatic Transition in Pathogenic TTR Gene Variant CarriersEuropean Journal of Neurology · 2026
11. Long-Term Efficacy and Safety of Acoramidis in ATTR-CM: Initial Report From the Open-Label Extension of the ATTRibute-CM TrialCirculation · 2024
12. Effect of Acoramidis on Recurrent and Cumulative Cardiovascular Outcomes in ATTR-CMJournal of the American College of Cardiology · 2025
13. Spatial Coordination of Electromagnetic Communication Infrastructure, AI Technology Attention and Regional E-commerce Development: Evidence from ChinaAdvanced Electromagnetics · 2026
14. Pilot Plant Study of the ZESTY Flash Hydrogen Direct Reduction Ironmaking ProcessJournal of Sustainable Metallurgy · 2026
15. MLB-01-003Neurology Open Access · 2026
16. Temperature-Dependent Crystallization Pathways ofthe Curcumin-Magnolol Coamorphous System: A Mechanistic Study IntegratingThermodynamics and KineticsCrystal Growth & Design · 2026
17. Analytical Derivation and Simplified Application of In-Plane Equivalent Static Wind Loads for Cantilever Arch Rings during ConstructionJournal of Bridge Engineering · 2026
18. Shear Behavior of Grouped Long Studs in Novel Noncellular Steel–UHPC Joints of Hybrid Girder Continuous Rigid-Frame BridgeJournal of Structural Engineering · 2026
19. Safety, Tolerability, Pharmacokinetics, Food Effect of Ribitol, and Its Effect on QTcF in Healthy Adults: First‐in‐Human, Randomized, Double‐Blind (Sponsor Unblinded), Placebo‐Controlled StudiesClinical Pharmacology in Drug Development · 2026
20. Effect of Acoramidis on Heart Failure–Related Health StatusJAMA Cardiology · 2026